NASDAQ: ANIX - Anixa Biosciences, Inc.

Rentabilität für sechs Monate: -8.5%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Anixa Biosciences, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Anixa Biosciences, Inc.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.

weitere details
Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 1987-01-01
ISIN US03528H1095
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.anixa.com
Цена ао 3.15
Preisänderung pro Tag: +5.66% (2.65)
Preisänderung pro Woche: +17.65% (2.38)
Preisänderung pro Monat: -5.41% (2.96)
Preisänderung über 3 Monate: +31.46% (2.13)
Preisänderung über sechs Monate: -8.5% (3.06)
Preisänderung pro Jahr: -11.39% (3.16)
Preisänderung über 3 Jahre: +7.69% (2.6)
Preisänderung über 5 Jahre: +56.42% (1.79)
Preisänderung seit Jahresbeginn: +10.67% (2.53)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 470.6 1
P/BV 6.7 1
P/E 0 0
EV/EBITDA -9.08 0
Gesamt: 2.13

Effizienz

Name Bedeutung Grad
ROA, % -53.29 0
ROE, % -56.63 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0168 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -80.91 0
Rentabilität Ebitda, % 42.59 6
Rentabilität EPS, % -14.9 0
Gesamt: 2.6
Weitere Details

Institutionen Volumen Aktie, %
Vanguard Group Inc 1392906 4.37
UBS Group AG 580578 1.82
Mission Wealth Management, LLC 501168 1.57
Laird Norton Trust Company, LLC 368835 1.16
Geode Capital Management, LLC 312472 0.98
Long Focus Capital Management, LLC 165701 0.52
Blackrock Inc. 156797 0.49
State Street Corporation 108500 0.34
Bank Of New York Mellon Corporation 96654 0.3
Susquehanna International Group, LLP 73303 0.23



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Amit Kumar Ph.D. CEO, Chairman & Co-Chair of CBAB 1.29M 1964 (61 Jahr)
Mr. Michael J. Catelani CPA, MBA President, COO, CFO & Corporate Secretary 788.83k 1967 (58 Jahre)
Mr. John Roop Senior Vice President of Engineering 275k 1950 (75 Jahre)
Dr. Pamela D. Garzone Ph.D. Chief Development Officer & Chair Breast Cancer Clinical Advisory Board 1955 (70 Jahre)

Adresse: United States, San Jose. CA, 3150 Almaden Expressway - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.anixa.com